A systematic review including 98 RCTs with a total of 9 506 subjects and 11 020 drug exposures was abstracted in DARE. The outcomes assessed were definitive cardiovascular events (death, nonfatal myocardial infarction, nonfatal stroke, revascularisation procedure) and episodes of new-onset or increased angina.
14 events occurred in 5 198 users of nifedipine (0.27%) compared to 24 events in 5 402 users (0.44%) of other active drug controls. The odds ratio for nifedipine monotherapy vs. combotherapy was non-significantly higher (OR 1.40, 95% CI 0.49 to 4.03).
Comment: The quality of evidence is downgraded by imprecise results (few outcome events).